FindTrial
Sign In

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05106179
Enrollment
1000
Registered
2021-11-03
Start date
2021-12-31
Completion date
2023-12-31
Last updated
2021-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Tumor, Spinal Hemangioma, Beta Blocker Toxicity

Keywords

β-blockers, Vertebral Hemangioma, Efficacy

Brief summary

Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.

Interventions

DRUGPropranolol Pill

Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.

DRUGAtenolol Pill

Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.

Sponsors

Center for Vascular Pathology, Moscow
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* vertebral hemangioma

Exclusion criteria

* symptomatic bradycardia * AV block * decompensated heart failure * asthma

Design outcomes

Primary

MeasureTime frameDescription
Reducing tumor growth3 monthsMRI
Reducing tumor6 monthsMRI
Life-quality3 months and 6 monthsValid questionnaires based on the ones, approved by EuroQol Organization

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026